0 CHECKOUT

Sweden Pharmaceuticals and Healthcare Report Q2 2016

  • ID: 3625517
  • February 2016
  • Region: Sweden
  • 88 pages
  • Business Monitor International
1 of 4

FEATURED COMPANIES

  • AstraZeneca
  • Meda
  • Medivir
  • Novartis
  • MORE

Sweden's epidemiological profile will continue to be attractive to manufacturers of medicines for non-communicable diseases. Despite the relative rapid uptake of innovative pharmaceuticals, the burden of chronic conditions will increase over the next 15 years. Presenting a challenge to drugmakers, like many other developed states, Sweden is introducing cost-containment measures to restrict the commercial opportunities available to drugmakers.

Headline Expenditure Projections

- Pharmaceuticals: SEK39.50bn (USD4.68bn) in 2015 to SEK39.79bn (USD4.68bn) in 2016; +0.74% in local currency terms and -0.1% in US dollar terms.

- Healthcare: SEK371.82bn (USD44.09bn) in 2015 to SEK381.68bn (USD44.88bn) in2016; +2.7% in local currency terms and 1.8% in US dollar terms.

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AstraZeneca
  • Meda
  • Medivir
  • Novartis
  • MORE

- Table: Headline Pharmaceuticals & Healthcare Forecasts (Sweden 2014-2020)

- SWOT

- Industry Forecast

- Pharmaceutical Market Forecast

- Table: Pharmaceutical Sales, Historical Data And Forecasts (Sweden 2012-2020)

- Healthcare Market Forecast

- Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Sweden 2012-2020)

- Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Sweden 2012-2020)

- Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Sweden 2012-2020)

- Prescription Drug Market Forecast

- Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Sweden 2012-2020)

- Patented Drug Market Forecast

- Table: Patented Drug Market Indicators, Historical Data And Forecasts (Sweden 2012-2020)

- Generic Drug Market Forecast

- Table: Generic Drug Market Indicators, Historical Data And Forecasts (Sweden 2012-2020)

- OTC Medicine Market Forecast

- Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Sweden 2012-2020)

- Pharmaceutical Trade Forecast

- Table: Pharmaceutical Trade Data And Forecasts (Sweden 2014-2020)

- Table: Pharmaceutical Trade Data And Forecasts local currency (Sweden 2014-2020)

- Industry Risk/Reward Index

- Western Europe Risk/Reward Index

- Sweden Risk/Reward Index

- Rewards

- Risks

- Regulatory Review

- Intellectual Property Issues

- Pricing Regime

- Reimbursement Regime

- Market Overview

- Healthcare Sector

- Table: Healthcare Resources (Sweden 2010-2015)

- Table: Healthcare Personnel (Sweden 2010-2015)

- Table: Healthcare Activity (Sweden 2010-2015)

- Research & Development

- Table: Drug Development Member Companies of SwedenBIO, 2015

- Clinical Trials

- Epidemiology

- Competitive Landscape

- Research-Based Industry

- Table: Multinational Market Activity

- Pharmaceutical Distribution

- Pharmaceutical Retail Sector

- Company Profile

- AstraZeneca

- Meda

- Medivir

- Novartis

- Swedish Orphan Biovitrum (SOBI)

- Demographic Forecast

- Table: Population Headline Indicators (Sweden 1990-2025)

- Table: Key Population Ratios (Sweden 1990-2025)

- Table: Urban/Rural Population & Life Expectancy (Sweden 1990-2025)

- Table: Population By Age Group (Sweden 1990-2025)

- Table: Population By Age Group % (Sweden 1990-2025)

- Glossary

- Methodology

- Pharmaceutical Expenditure Forecast Model

- Healthcare Expenditure Forecast Model

- Notes On Methodology

- Risk/Reward Index Methodology

- Index Overview

- Table: Pharmaceutical Risk/Reward Index Indicators

- Indicator Weightings

Note: Product cover images may vary from those shown
3 of 4

- AstraZeneca
- Meda
- Medivir
- Novartis
- Swedish Orphan Biovitrum (SOBI)

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Amneal Pharmaceuticals LLC.
  • Amgen Inc.
  • LEO Laboratories Ltd.
  • Pfizer Inc.
  • Roche Diagnostics Ltd.
  • Merck & Co., Inc.
  • Sanofi S.A.